biogen alzheimer’s

The analysts started scratching their heads during an earnings conference call as there was a lack of clarity in the delay in filing of Biogen's Alzheimer's drug. Last year, Biogen stock soared by 27% after the company optimistically said it would file an application with the US Food and Drug...